Alnylam Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Alnylam Pharmaceuticals generated cash of $104,156,000, which is more than the previous year. Cash used in financing activities reached the amount of $172,131,000 last year. Net change in cash is therefore -$53,672,000.
Cash Flow
| 2014 | -165.64M | -548.81M | 736.46M |
|---|---|---|---|
| 2015 | -189.14M | -321.32M | 616.17M |
| 2016 | -307.70M | 142.59M | 177.83M |
| 2017 | -382.78M | -290.36M | 1.12B |
| 2018 | -562.61M | 272.94M | 65.47M |
| 2019 | -278.42M | -417.67M | 823.18M |
| 2020 | -614.96M | -435.51M | 994.97M |
| 2021 | -641.69M | -273.3M | 1.24B |
| 2022 | -541.27M | 169.35M | 425.75M |
| 2023 | 104.15M | -336.35M | 172.13M |
ALNY Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 868.55M | 822.15M | 499.04M | 549.62M | 422.63M | 646.83M | 193.61M | 180.89M | 75.17M | 53.16M |
Operating activities | ||||||||||
Net income | -440.24M | -1.13B | -852.82M | -858.28M | -886.11M | -761.49M | -490.87M | -410.10M | -290.07M | -360.39M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 97.03M | 85.55M | 89.69M | 74.43M | 54.36M | 6.43M | 13.36M | 15.13M | 19.05M | 11.92M |
Stock-based compensation expense | 221.68M | 230.64M | 165.71M | 139.87M | 174.84M | 0 | 92.81M | 75.52M | 45.78M | 33.06M |
| Deferred income tax benefit | 221.68M | 230.64M | 165.71M | 139.87M | 174.84M | 0 | 92.81M | 75.52M | 45.78M | 33.06M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -87.93M | -45.59M | -101.79M | -56.23M | -24.23M | 15.24M | -10.66M | -15.03M | 31.63M | -35.68M |
Inventories | 18.36M | -34.13M | -26.41M | -35.42M | -32.41M | -22.64M | 10.85M | 5.39M | -477K | 3.29M |
Accounts payable | 80.84M | 191.76M | 88.24M | 117.37M | 36.60M | 15.47M | -4.93M | 10.09M | 1.67M | 8.84M |
Cash generated by operating activities | 104.15M | -541.27M | -641.69M | -614.96M | -278.42M | -562.61M | -382.78M | -307.70M | -189.14M | -165.64M |
Investing activities | ||||||||||
Purchases Of Investments | -1.88B | -1.97B | -1.65B | -2.02B | -2.07B | -1.10B | -903.45M | -759.31M | -1.03B | -977.77M |
Investments In Property Plant And Equipment | -62.21M | -72.05M | -76.37M | -70.36M | -140.15M | -126.88M | -104.20M | -64.55M | -12.95M | -8.96M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -336.35M | 169.35M | -273.3M | -435.51M | -417.67M | 272.94M | -290.36M | 142.59M | -321.32M | -548.81M |
Financing activities | ||||||||||
Common Stock Issued | 147.46M | 259.36M | 246.26M | 99.49M | 781.9M | 0 | 1.16B | 14.30M | 585.41M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | -3.46M | -257K | -596K | -378K | -15.99M |
Repayments of term debt | 0 | 254.00M | -1B | -686.59M | 0 | 0 | -120M | 0 | 0 | 0 |
Cash used in financing activities | 172.13M | 425.75M | 1.24B | 994.97M | 823.18M | 65.47M | 1.12B | 177.83M | 616.17M | 736.46M |
Net Change In Cash | -53.67M | 46.40M | 323.10M | -50.58M | 126.99M | -224.20M | 451.74M | 12.72M | 105.71M | 22.01M |
Cash at end of period | 814.88M | 868.55M | 822.15M | 499.04M | 549.62M | 422.63M | 645.36M | 193.61M | 180.89M | 75.17M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |